VALBIOTIS Presents the First Market Data on Untreated LDL-hypercholesterolemia For TOTUM-070, And Announces the Initiation of The Phase II Clinical Study HEART
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / eligible for the PEA/SME), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, presents the target market for its active substance TOTUM-070, for untreated mild to moderate LDL-hypercholesterolemia. The Phase II clinical study has been initiated and will begin as soon as authorizations are received from the French National Agency for the Safety of Medicines and Health Products (ANSM) and the French Committee for the Protection of Persons (CPP).
TOTUM-070 is an innovative active substance derived from food plant extracts, without phytosterols nor red yeast rice, developed to act on lipid metabolism in individuals with hypercholesterolemia.
Once development is complete, this new Health Nutrition product will be positioned mainly for people with LDL-hypercholesterolemia, at levels up to 190 mg/dL, with a moderate overall cardiovascular risk. TOTUM-070 could be advised to this large population for whom no first-line treatment is currently recommended. It aims at lowering LDL-cholesterol levels and thereby reducing overall cardiovascular risk.
Dr. Josep INFESTA, MD, Head of Business Development at VALBIOTIS2, explains: "Excess LDL-cholesterol is a widespread cardiovascular risk factor, found in nearly 40% of the world's adult population, based on WHO data. In line with our prevention strategy, our active substance TOTUM-070 is a new solution for at-risk individuals, yet untreated according to the current guidelines. Market data supports our analysis: nearly 1.2 billion euros are spent on non-drug products for LDL-cholesterol in the USA and the 5 major European countries. TOTUM-070 is expected to show strong efficacy at the end of its clinical development, which would give it a clear advantage in the untreated hypercholesterolemia market."
The Phase II randomized, double-blind, placebo-controlled clinical study will include 120 people with untreated moderate hypercholesterolemia between 130 and 190 mg/dL. Participants will be divided into two equivalent arms of 60 people, receiving TOTUM-070 or placebo for six months. The primary endpoint of the study will be the reduction of blood LDL-cholesterol levels, with several secondary endpoints of interest. The study has just been initiated, the protocol having been submitted to the ANSM and CPP. The first subject's first visit is scheduled for the first quarter of 2021, and results are expected by the end of 2021 or early 2022.
Following VALBIOTIS’ business model, the objective is to conclude a partnership and licensing agreement for the marketing of TOTUM-070, with a global health player.
Untreated hypercholesterolemia: a major market for non-drug products
In the 5 major European countries (France, Germany, Italy, Spain, United Kingdom) and the United States, an estimated 174 million adults have high LDL-cholesterol1,3. The general public in these countries is very familiar with this health issue, supporting wide screening, and diagnosis rates are high, approaching 50%. The diagnosed population currently stands at 83 million people1.
However, and in accordance with recommendations, only subjects at high overall cardiovascular risk benefit from treatment. A large proportion of those diagnosed therefore already uses non-drug products, particularly in the USA (54% of individuals diagnosed), the UK (58%), France (34%) and Germany (35%)1. The market for such LDL-cholesterol products is currently estimated at nearly €1.2 billion in these regions, including more than €600 million in the United States1.
Persons aged more than 25 years old
Persons diagnosed with elevated LDL-cholesterol (millions)
% of persons aged more than 25 years old, diagnosed
LDL-hypercholesterolemia treatment: the need for effective products from the earliest stages
According to current European and American recommendations (ESC, AAC, EAS4), the treatment of LDL-hypercholesterolemia is individually defined, based on LDL-cholesterol levels and overall cardiovascular risk5,6. The SCORE (Systematic Coronary Risk Evaluation) index, for example, classifies patients according to five risk levels, from "low" to "very high", taking into account each individual's cardiovascular risk factors (tobacco, alcohol, overweight, high blood pressure, etc.).
The prescription of first-line lipid-lowering treatment7 is currently indicated for patients with high cardiovascular risk and/or high LDL-cholesterol levels5,6.
The vast majority of people at lower or moderate risk are first advised to make lifestyle changes (diet and physical activity), with the prospect of treatment if blood LDL-cholesterol levels remain uncontrolled.
Professor Jean-Marie BARD, PharmD, PhD, University Professor and Hospital Practitioner at Nantes University Hospital, scientific advisor for the Phase II clinical study, confirms: "We now know how to treat high-risk patients with effective drugs, generally statins, which have a favorable risk/benefit ratio in such cases. Nevertheless, individual variability exists and adverse events have been identified, leading to non-compliance and treatment discontinuation. Moreover, for all other people, with no imminent cardiovascular risk, only lifestyle changes can be proposed, with variable results. For these two populations, we need additional effective and well-tolerated clinical tools that rapidly reduce LDL-cholesterol before the situation deteriorates. TOTUM-070 could very well meet this need."
LDL-cholesterol, a key cardiovascular risk factor
According to international scientific societies, LDL-cholesterol is considered the number one risk factor for atherosclerosis6.
When present in excessive concentrations in the blood, LDL-cholesterol leads to the formation and deposition of atheromatous plaques (essentially the accumulation of fats and blood cells) on artery walls: this is atherosclerosis, a severe cardiovascular disease that causes strokes, myocardial infarction and peripheral artery disease5. Atherosclerosis is associated with very high morbidity and mortality: the rupture of an atheromatous plaque, for example, is the cause of 80% of sudden deaths in adults8.
Globally every year, excess blood LDL-cholesterol is directly responsible for 4.3 million deaths and the loss of 88.7 million years of healthy life9.
VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.
VALBIOTIS has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of nutritional health solutions designed to reduce the risk of major metabolic diseases, based on a multi-target approach and made possible by the use of plant-based ingredients.
Its products are intended to be licensed to players in the health world.
VALBIOTIS was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63).
VALBIOTIS is a member of the “BPI Excellence” network and received “Innovative Company“ status awarded by BPI France. Valbiotis has also been awarded “Young Innovative Company” status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). VALBIOTIS is a PEA-SME eligible company.
Find out more about VALBIOTIS: www.valbiotis.com
1 AEC Partners Data, 2019
2 External consultant
3 Blood levels of LDL-cholesterol greater than 100 or 130 mg/dL, based on available data
4 European Society of Cardiology, American Association of Cardiology, European Atherosclerosis Society
5 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk
6 2018 Guideline on the Management of Blood Cholesterol, a report from the American College of Cardiology / American Heart Association, Journal Of The American College Of Cardiology, 2019
7 Treatment to reduce the level of lipids in the blood (e.g., cholesterol and triglycerides)
9 GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: A systematic analysis for the Global Burden of Disease study 2015. Lancet. 2016.
Name : VALBIOTIS
ISIN Code: FR0013254851
Mnemonic Code: ALVAL
EnterNext© PEA-SME 150
This press release contains forward-looking statements about VALBIOTIS’ objectives, based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be affected by changes in economic conditions and financial markets, as well as a certain number of risks and uncertainties, including those described in the VALBIOTIS registration document, filed with the French Financial Markets Regulator (AMF) on 31 July 2020 (application number R 120-018). This document is available on the Company’s website (www.valbiotis.com).
This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, VALBIOTIS’ shares or securities in any country.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
VALBIOTIS / CORPORATE COMMUNICATION
Carole ROCHER / Marc DELAUNAY
+33 5 46 28 62 58
ACTIFIN / FINANCIAL COMMUNICATION
33 1 56 88 11 14
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EIG-Led Consortium Closes $12.4 Billion Infrastructure Deal with Aramco18.6.2021 21:02:00 CEST | Press release
EIG,a leading institutional investor to the global energy sector and one of the world’s leading infrastructure investors, today announced the closing of its previously announced transaction with Saudi Arabian Oil Co. (“Aramco”), under which a consortium of investors acquired a 49% equity stake in Aramco Oil Pipelines Company (“Aramco Oil Pipelines”), a newly formed entity with rights to 25 years of tariff payments for oil transported through Aramco’s stabilized crude oil pipeline network. The EIG-led co-investment process in Aramco Oil Pipelines attracted a global group of leading institutional investors from China, the Kingdom of Saudi Arabia, Korea, the United Arab Emirates and the United States including, amongst others, Mubadala Investment Company, an Abu Dhabi Sovereign Investor, Silk Road Fund, Hassana and Samsung Asset Management. R. Blair Thomas, EIG Chairman and CEO, said: “We are pleased to have completed this transaction with Aramco, a preeminent global energy supplier. The
Moody's ESG Solutions: V.E provides Second Party Opinion on Desjardins’ Sustainable Bond Framework18.6.2021 18:13:00 CEST | Press release
Moody's ESG Solutions announced today that V.E has provided a Second Party Opinion (SPO) on Desjardins’ Sustainable Bond Framework. The framework will be used to finance and refinance projects tied to eight environmental categories and three social categories, including Renewable Energy, Green Buildings, and Affordable Housing. In V.E’s opinion, the framework is aligned with the four core components of the Green Bond Principles (2018) and the Social Bond Principles (2020). “In our assessment, the bonds issued via this framework will provide an ‘advanced’ contribution to sustainability objectives, as we see significant and consistent evidence that the proceeds will be allocated to environmentally and socially focused projects throughout Canada and several emerging markets,” said Patrick Mispagel, Managing Director – Sustainable Finance at Moody’s ESG Solutions. “We expect to see growth in sustainability efforts in North America in order to meet increasing global regulatory requirements
Potential sale of HSBC SFH (France): Signing of a Memorandum of Understanding18.6.2021 15:30:00 CEST | Press release
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION HSBC Continental Europe (‘HBCE’) has today signed a Memorandum of Understanding (‘MOU’) with Promontoria MMB SAS (‘My Money Group’), its subsidiary Banque des Caraïbes SA (the ‘Purchaser’) and My Money Bank (‘MMB’), regarding the potential sale of HBCE’s retail banking business in France. My Money Group, MMB and the Purchaser are under the control, directly or indirectly, of funds and accounts managed or advised by Cerberus Capital Management L.P. The potential sale includes: HBCE’s French retail banking business; the Crédit Commercial de France (‘CCF’) brand; and, subject to the satisfaction of relevant conditions, HBCE’s 3% ownership interest in Crédit Logement, its 100% ownership interest in HSBC SFH (France) (‘HSFH’), and the transfer of rights and obligatio
UFC® Names Lumen® the Official Metabolic Tracker of the UFC Performance Institute18.6.2021 15:30:00 CEST | Press release
UFC®, the world’s premier mixed martial arts organization, has named Lumen® the Official Metabolic Tracker of the UFC Performance Institute®. To launch the new partnership, select UFC athletes will be using Lumen as a tool to optimize their performance under the guidance of the nutrition team at the UFC Performance Institute (UFC PI). These athletes will have access to real-time metabolic data to help improve their nutrition, performance, and body composition through optimizing their metabolic health and flexibility. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210618005278/en/ Dustin Poirier and Lumen (Photo: Business Wire) “The UFC PI strives to support athletes in fueling their body to achieve championship performances while also maintaining optimal health, all while meeting the weight management demands of mixed martial arts,” said Clint Wattenberg, UFC PI Director of Performance Nutrition. “Metabolic health and metabo
Sale of Retail Banking Business in France18.6.2021 15:30:00 CEST | Press release
HSBC Continental Europe (‘HBCE’) has today signed a Memorandum of Understanding (‘MOU’) with Promontoria MMB SAS (‘My Money Group’), its subsidiary Banque des Caraïbes SA (the ‘Purchaser’) and My Money Bank (‘MMB’), regarding the potential sale of HBCE’s retail banking business in France. My Money Group, MMB and the Purchaser are under the control, directly or indirectly, of funds and accounts managed or advised by Cerberus Capital Management L.P. Commenting on the Potential Transaction, Jean Beunardeau, HBCE CEO said: “This potential transaction is an important step towards achieving our strategic goal of being a leading wholesale bank in Continental Europe for Corporate and Investment Banking, Markets and Private Banking, anchored in Paris, connecting our customers to HSBC’s global network, and providing access to Continental Europe for HSBC’s customers around the world. As importantly, this potential transaction would allow HSBC’s French retail banking business to be sold to an expe
Hilton Doubles Down on Las Vegas Growth with Rapidly Expanding Portfolio and Grand Return to the Strip18.6.2021 15:07:00 CEST | Press release
After revolutionizing the Las Vegas hospitality experience decades ago, Hilton is building on its storied legacy in time for the return to travel by almost doubling its presence in the sought-after global destination over the past three years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210618005335/en/ Resorts World Las Vegas – Exterior (Photo: Business Wire) The company is slated to have more than 30 hotels and over 11,000 rooms across 12 brands in the market by the end of 2021. On the heels of Virgin Hotels Las Vegas, CurioCollection by Hilton’s June opening celebration, and just weeks before the anticipated debut of Conrad Hotels & Resorts, LXR Hotels & Resorts and Hilton Hotels & Resorts at the integrated Resorts World Las Vegas complex, Hilton is making an epic return to this top-tier travel destination, bringing new premium and luxury brands to the Strip. “Hilton helped create the Las Vegas we know today – the ente
Toshiba's Chairperson of the Board of Directors Issues Open Letter to Its Shareholders18.6.2021 11:06:00 CEST | Press release
Toshiba Corporation (TOKYO:6502) today announced that Osamu Nagayama, Chairperson of Toshiba’s Board of Directors, has issued an open letter to the company's shareholders. The full text of the letter is as follows: Dear Shareholders As the Chairperson of the Board of Directors of Toshiba Corporation ("Toshiba", the "Company"), I would like to express my deep regret regarding recent unacceptable events at the Company which have eroded your trust in us. You would have seen that we have already taken decisive and immediate action following the release of the Investigation Report, amending the slate of nominees for directors, committee members and executive officers ahead of the upcoming AGM on June 25. I, together with the Board, am fully committed to ensuring we improve your Company's governance fundamentally and enhance its corporate value. United, we shall be taking the following concrete steps with urgency: In order to stop recurrence, we will conduct an inquiry, with third party part